Mirae Asset Global Investments Co., Ltd. Fate Therapeutics Inc Transaction History

Mirae Asset Global Investments Co., Ltd.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 01, 2024	BUY	$3.54 - $8.35 $208,275 - $491,272	58,835 New	58,835 $431,000
Q2 2023 Aug 10, 2023	SELL	$4.76 - $6.59 $96,827 - $134,053	-20,342 Reduced 22.11%	71,679 $341,000
Q1 2023 May 04, 2023	BUY	$4.24 - $11.12 $106,839 - $280,201	25,198 Added 37.71%	92,021 $524,000
Q4 2022 Feb 09, 2023	BUY	$9.86 - $23.83 $85,170 - $205,843	8,638 Added 14.85%	66,823 $674,000
Q3 2022 Nov 10, 2022	BUY	$21.04 - $36.06 $55,945 - $95,883	2,659 Added 4.79%	58,185 $1.3 Million
Q2 2022 Jul 26, 2022	BUY	$17.78 - $42.39 $529,577 - $1.26 Million	29,785 Added 115.71%	55,526 $1.38 Million
Q1 2022 May 10, 2022	BUY	$29.67 - $60.28 $130,874 - $265,895	4,411 Added 20.68%	25,741 $998,000
Q4 2021 Feb 08, 2022	BUY	$47.84 - $64.34 $176,433 - $237,285	3,688 Added 20.9%	21,330 $1.25 Million
Q3 2021 Nov 15, 2021	BUY	$59.27 - $95.73 $207,326 - $334,863	3,498 Added 24.73%	17,642 $1.05 Million
Q2 2021 Aug 11, 2021	BUY	$67.25 - $92.52 $135,239 - $186,057	2,011 Added 16.57%	14,144 $1.23 Million
Q1 2021 May 13, 2021	BUY	$72.16 - $117.4 $875,517 - $1.42 Million	12,133 New	12,133 $1 Million

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $215M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.